Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29841174 | 1.00 | POLB (0.56) | POLBTSHRSMN1; SMN2CYP1A2FLT1 | |
| SCHEMBL13265509 | 0.89 | POLB (0.65) | POLBTSHRSMN1; SMN2CYP1A2ATM | |
| SCHEMBL26907189 | 0.82 | POLB (0.50) | POLBTSHRSMN1; SMN2CYP1A2ATM | |
| SCHEMBL1786764 | 0.79 | POLB (0.68) | POLBTSHRSMN1; SMN2CYP1A2ATM | |
| SCHEMBL29480990 | 0.79 | POLB (0.68) | POLBTSHRSMN1; SMN2CYP1A2ATM | |
| SCHEMBL26907358 | 0.78 | PARP1 (0.52) | POLBTSHRSMN1; SMN2CYP1A2ATM | |
| SCHEMBL26423155 | 0.73 | POLB (0.60) | POLBTSHRSMN1; SMN2CYP1A2ATM | |
| SCHEMBL30319341 | 0.73 | POLB (0.60) | POLBTSHRSMN1; SMN2CYP1A2ATM | |
| SCHEMBL13721278 | 0.72 | POLB (1.00) | POLBTSHRSMN1; SMN2CYP1A2ATM | |
| SCHEMBL22552378 | 0.72 | POLB (0.59) | POLBTSHRSMN1; SMN2CYP1A2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-30 | — | — | US | disclosed |
| CN-117355303-A | Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic disorders | 佛罗里达大学研究基金会公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4284372-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-0970070-B1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-6710047-B2 | INHIBIT THE ACTIVITY OF THE VEGF RECEPTOR TYROSINE KINASE AND THE GROWTH OF TUMOURS | NOVARTIS AG (CH) | 2004-03-23 | — | — | US | disclosed |
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2003-10-09 | — | — | US | disclosed |
| US-6514974-B2 | 1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine for example | NOVARTIS AG (CH) | 2003-02-04 | — | — | US | disclosed |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2002-07-11 | — | — | US | disclosed |
| US-6258812-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS AND CARDIOVASCULAR DISORDERS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | POLB 3071/4885TSHR 1614/4885SMN1; SMN2 3492/4885 |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | POLB 751/4885TSHR 3461/4885SMN1; SMN2 30/4885 |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | POLB 2805/4885TSHR 1581/4885SMN1; SMN2 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.